This week, we’re in Barcelona, Spain, to visit Leukos Biotech, whose goal is to develop new treatments and diagnostic tools for Leukaemia.

This Spanish Biotech Is Developing Stem-Cell Targeted Leukemia Treatments

Visit our map to check out some more of Europe’s exciting biotech companies.

Mission: Founded in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute (IJC), Leukos Biotech has raised €3.5M in funding and has identified a new therapeutic target against leukemic stem cells in acute myeloid leukemia (AML). The company plans to validate the target in a Phase II clinical trial.

Furthermore, Leukos Biotech holds a license for proprietary use of a family of drugs, developed at IJC that could be used towards the diagnosis and treatment AML patients and assessing their further prognosis.

Leukos’ lead project is a diagnosis kit based on Phase IIa data. Additional projects in the pipeline target other blood cancers.

Comment: AML has a high unmet patient need. Leukos’ approach could bring significant advances to patients and its regenerative technology has broad potential. I was surprised to learn that although remission rates for AML patients after chemotherapy range from 50-85%, the majority of patients will relapse and succumb to the disease within 5 years. The chemoresistance of certain leukemia stem cells may be responsible for the observed maintainance and reinitiation of the disease. Leukos’ endeavors highlight the potential of regenerative medicine has in a variety of applications.

Previous post

Biosensors Bring HIV Test to Patients for Instant Results

Next post

London Biotech Uses Unique Double Mechanism of Action to Treat Cystic Fibrosis

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.